Analyst Valuation Suggests 125% Upside for Oculis Holding AG Amid Biotech Volatility
A recent analyst valuation of Oculis Holding AG has set the company’s intrinsic value at €36 per share, significantly higher than its current market price, suggesting potential upside for long-term investors.
3 minutes to read
